FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904201237> ?p ?o ?g. }

• W2904201237 endingPage "474" @default.
• W2904201237 startingPage "474" @default.
• W2904201237 abstract "Abstract Background: The international criteria for definition CR, requires, among other parametres, a negative IF both in serum and urine; however, urine IF is not always performed. In the belief that this lack could bias the comparison between trials, the First Trial Independent Response Adjudication Committee (FTIRAC) recommended that patients who met all CR criteria except the availability of a urine IF should be classified as VGPR (Blood 2014; 124 [abstract 3460]) but this criteria is not always applied which may translate into differences in CR rates between trials. However, it is unknown (1) if this conversion has a real clinical basis, (2) if urine IF results alter the clinical meaning of CR, or (3) on the contrary, if patients in CR with and those without a documented negative urine IF have a similar prognosis, in which case this rule would underestimate the CR rates, increasing the biases and magnifying the problem that was intended to improve. Aim: To determine the value of urine negative IF in the definition of CR. Methods: 459 patients were enrolled into the GEM2012MENOS65phase3 trial and treated with 6 induction cycles of bortezomib, lenalidomide, and dexamethasone, HDT/ASCT and 2 consolidation courses. Evaluable patients were enrolled in a maintenance trail (NCT02406144). Excluding 6 patients who discontinued early, 453 were evaluable. At diagnosis, the M-component was detected exclusively in serum in 173 of these patients and in serum and urine in 212 patients; 68 patients had pure Bence-Jones M-protein (BJMM). The protein studies were performed in each cycle. At the time of negative IF, bone marrow aspirates were analysed for count of PCs and monitoring minimal residual disease (MRD) following EuroFlow SOPs (median limit of detection of 3x10-6).The response classifications were made according to the IMWG criteria, but we applied the FTIRAC criteria, and, patients with <5% BM PCs and negative serum IF but with unavailable urine IF (or vice versa for patients with BJMM) were classified as VGPR. For the purpose of this study, we called these uncertain CR (uCR). Stringent Complete Responses were classified as CR.Median follow-up was 40 months. Results: Overall, 3774 protein evolution studieswere performed: 691 (18%) in CR, 802 (21%) in uCR and 868 (23%)in VGPR.In all patients with M-component exclusively in serum at diagnosis butwith negative serum IF after treatment, and available urine IF (174 patients, 1476 protein studies), the urine paraprotein IF detection rate was 0%. In patients with a positive M-component in both serum and urine at diagnosis, but with negative serum IF after treatment, and available urine IF (212patients, 1763 protein assessment), 11 protein evaluations in 6 patients (2.8%) tested positive in urine; in other words: in 97,2% of the patients a negative serum IF predicts for negative urine.Since MRD is a robust subrogate of depth of responses (J ClinOncol. 2017;35:2900-10), we compared MRD-verates in patients achieving CR, uCR and VGPR. Interestingly, there were no significant differences in the post-consolidation MRD-verates among patients in CR vsthose in uCR (68% vs 77%, P=.1), whereas significant differences were seen when comparing CR and uCRvs VGPR (23% in the latter; P≤.0001). Accordingly, a landmark analysis performed at HDT/ASCT, - time pointselected to improve the PFS observation time- , showed 2-year PFS rates of 88%, 87% and 77% inpatients in CR, uCR and VGPR, no differences in 2-year PFS rates between patients in CR vsuCR (P=.6) while patients in VGPR showed inferior PFS compared with those in uCR (P=.04). With this landmark, the MRD-negativity ratios are similar to those described after consolidation. Conclusions: In MM patients with M-component exclusively in serum at diagnosis, urine IF follow-up is unnecessary, while in patients with paraprotein in both serum and urine,a negative serum IF response is accompanied by a negative urinary IF in 97.8% of patients. Moreover, patients with CR but without available IF in urine display similar MRD-veand PFS rates compared withthose in CR. By contrast, MRD-veand PFS values in these patients are significantly superior to those in VGPR. Thus, our results suggest that, except for those with pure BJMM, patients fulfilling CR criteria but with unavailable urine IF should be classified as CR instead of VGPR. This data discourages the application of the FTIRAC conversion criteria. Also, the IMWG criteria for CR should be reviewed. Disclosures Rosinol: Janssen, Celgene, Amgen, Takeda: Honoraria. Puig:Janssen: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria; Celgene: Honoraria, Research Funding. Garcia-Sanz:Affimed: Research Funding. Oriol:Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Rios:Amgen, Celgene, Janssen, and Takeda: Consultancy. De La Rubia:Ablynx: Consultancy, Other: Member of Advisory Board. Mateos:Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. San-Miguel:Brystol-Myers Squibb: Consultancy; Celgene: Consultancy; Novartis: Consultancy; Takeda: Consultancy; Amgen: Consultancy; MSD: Consultancy; Janssen: Consultancy; Sanofi: Consultancy; Roche: Membership on an entity's Board of Directors or advisory committees. Bladé:Celgene: Honoraria; Amgen: Honoraria; Janssen: Honoraria. Lahuerta:Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees." @default.
• W2904201237 created "2018-12-22" @default.
• W2904201237 creator A5012150772 @default.
• W2904201237 creator A5013568680 @default.
• W2904201237 creator A5015898454 @default.
• W2904201237 creator A5028963447 @default.
• W2904201237 creator A5029159537 @default.
• W2904201237 creator A5029238392 @default.
• W2904201237 creator A5029958963 @default.
• W2904201237 creator A5030696673 @default.
• W2904201237 creator A5031837957 @default.
• W2904201237 creator A5032722606 @default.
• W2904201237 creator A5034182883 @default.
• W2904201237 creator A5047672322 @default.
• W2904201237 creator A5047866471 @default.
• W2904201237 creator A5051606383 @default.
• W2904201237 creator A5054952877 @default.
• W2904201237 creator A5056460838 @default.
• W2904201237 creator A5057189669 @default.
• W2904201237 creator A5058005126 @default.
• W2904201237 creator A5059482051 @default.
• W2904201237 creator A5059800672 @default.
• W2904201237 creator A5065757435 @default.
• W2904201237 creator A5071364391 @default.
• W2904201237 creator A5075422618 @default.
• W2904201237 creator A5077870725 @default.
• W2904201237 creator A5077975123 @default.
• W2904201237 creator A5081131857 @default.
• W2904201237 creator A5089163384 @default.
• W2904201237 date "2018-11-29" @default.
• W2904201237 modified "2023-10-18" @default.
• W2904201237 title "Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial" @default.
• W2904201237 doi "https://doi.org/10.1182/blood-2018-99-115050" @default.
• W2904201237 hasPublicationYear "2018" @default.
• W2904201237 type Work @default.
• W2904201237 sameAs 2904201237 @default.
• W2904201237 citedByCount "0" @default.
• W2904201237 crossrefType "journal-article" @default.
• W2904201237 hasAuthorship W2904201237A5012150772 @default.
• W2904201237 hasAuthorship W2904201237A5013568680 @default.
• W2904201237 hasAuthorship W2904201237A5015898454 @default.
• W2904201237 hasAuthorship W2904201237A5028963447 @default.
• W2904201237 hasAuthorship W2904201237A5029159537 @default.
• W2904201237 hasAuthorship W2904201237A5029238392 @default.
• W2904201237 hasAuthorship W2904201237A5029958963 @default.
• W2904201237 hasAuthorship W2904201237A5030696673 @default.
• W2904201237 hasAuthorship W2904201237A5031837957 @default.
• W2904201237 hasAuthorship W2904201237A5032722606 @default.
• W2904201237 hasAuthorship W2904201237A5034182883 @default.
• W2904201237 hasAuthorship W2904201237A5047672322 @default.
• W2904201237 hasAuthorship W2904201237A5047866471 @default.
• W2904201237 hasAuthorship W2904201237A5051606383 @default.
• W2904201237 hasAuthorship W2904201237A5054952877 @default.
• W2904201237 hasAuthorship W2904201237A5056460838 @default.
• W2904201237 hasAuthorship W2904201237A5057189669 @default.
• W2904201237 hasAuthorship W2904201237A5058005126 @default.
• W2904201237 hasAuthorship W2904201237A5059482051 @default.
• W2904201237 hasAuthorship W2904201237A5059800672 @default.
• W2904201237 hasAuthorship W2904201237A5065757435 @default.
• W2904201237 hasAuthorship W2904201237A5071364391 @default.
• W2904201237 hasAuthorship W2904201237A5075422618 @default.
• W2904201237 hasAuthorship W2904201237A5077870725 @default.
• W2904201237 hasAuthorship W2904201237A5077975123 @default.
• W2904201237 hasAuthorship W2904201237A5081131857 @default.
• W2904201237 hasAuthorship W2904201237A5089163384 @default.
• W2904201237 hasBestOaLocation W29042012371 @default.
• W2904201237 hasConcept C126322002 @default.
• W2904201237 hasConcept C126894567 @default.
• W2904201237 hasConcept C141071460 @default.
• W2904201237 hasConcept C159654299 @default.
• W2904201237 hasConcept C163864487 @default.
• W2904201237 hasConcept C203014093 @default.
• W2904201237 hasConcept C2776364478 @default.
• W2904201237 hasConcept C2778808339 @default.
• W2904201237 hasConcept C2780026642 @default.
• W2904201237 hasConcept C2780401358 @default.
• W2904201237 hasConcept C535046627 @default.
• W2904201237 hasConcept C542903549 @default.
• W2904201237 hasConcept C71924100 @default.
• W2904201237 hasConceptScore W2904201237C126322002 @default.
• W2904201237 hasConceptScore W2904201237C126894567 @default.
• W2904201237 hasConceptScore W2904201237C141071460 @default.
• W2904201237 hasConceptScore W2904201237C159654299 @default.
• W2904201237 hasConceptScore W2904201237C163864487 @default.
• W2904201237 hasConceptScore W2904201237C203014093 @default.
• W2904201237 hasConceptScore W2904201237C2776364478 @default.
• W2904201237 hasConceptScore W2904201237C2778808339 @default.
• W2904201237 hasConceptScore W2904201237C2780026642 @default.
• W2904201237 hasConceptScore W2904201237C2780401358 @default.
• W2904201237 hasConceptScore W2904201237C535046627 @default.
• W2904201237 hasConceptScore W2904201237C542903549 @default.
• W2904201237 hasConceptScore W2904201237C71924100 @default.
• W2904201237 hasIssue "Supplement 1" @default.
• W2904201237 hasLocation W29042012371 @default.
• W2904201237 hasOpenAccess W2904201237 @default.
• W2904201237 hasPrimaryLocation W29042012371 @default.
• W2904201237 hasRelatedWork W149422118 @default.
• W2904201237 hasRelatedWork W2047967234 @default.

• next